Veterinary Medicines

Fatrocef L.C. 75 mg Maść dowymieniowa

Authorised
  • Cefquinome sulfate
Download as PDF

Product identification

Medicine name:
Fatrocef L.C. 75 mg Maść dowymieniowa
Active substance:
  • Cefquinome sulfate
Target species:
  • Cattle
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Cefquinome sulfate
    88.90
    milligram(s)
    /
    1.00
    milligram(s)
Pharmaceutical form:
  • Intramammary ointment
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle
      • Meat and offal
        5
        week
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51DE90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Poland
Available in:
  • Poland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • URPL
Authorisation number:
  • 2668
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 6/02/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 6/02/2023
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 6/02/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."